Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study

BACKGROUND: Generic formulations of imatinib mesylate have been introduced in Western Europe since 2017 to treat patients with chronic myeloid leukemia (CML). However, results on the safety and efficacy of generic formulations are contrasting. The aim of this study was to investigate the safety and...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Res
Main Authors: Gemelli, Maria, Elli, Elena Maria, Elena, Chiara, Iurlo, Alessandra, Intermesoli, Tamara, Maffioli, Margherita, Pungolino, Ester, Carraro, Maria Cristina, D’Adda, Mariella, Lunghi, Francesca, Anghileri, Michela, Polverelli, Nicola, Rossi, Marianna, Bacciocchi, Mattia, Bono, Elisa, Bucelli, Cristina, Passamonti, Francesco, Antolini, Laura, Gambacorti-Passerini, Carlo
Formato: Artigo
Idioma:Inglês
Publicado em: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2020
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7536566/
https://ncbi.nlm.nih.gov/pubmed/32792470
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5045/br.2020.2020130
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados